MedTrace Logo

Observational Program, Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19

NCT05083039 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2023-02-08

No results posted yet for this study

Summary

Observational program, double-blind, placebo-controlled to study the preventive efficacy of the BiVac polio (Oral polio vaccine, divalent, live attenuated of types 1 and 3 vaccine against the incidence of acute respiratory infections, including COVID-19

Conditions

  • Coronavirus Infections
  • Vaccine
  • Polio

Sponsors & Collaborators

  • Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-05-14
Primary Completion
2020-12-14
Completion
2021-09-03

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05083039 on ClinicalTrials.gov